[1] Perez conducted a fellowship in hematology and oncology at the Martinez VA Medical Center through the UC Davis School of Medicine.
[4] [5] Prior to joining Bolt, she worked as the Vice President and Head of the BioOncology-U.S. Medical Affairs unit at Genentech from 2015 to 2018, where she led the development and conduct of translational studies with registrational intent, including engaging in discussions with the FDA.
Dr. Perez has also been involved in multiple diversity leadership initiatives with ASCO and AACR, and currently serves as the Chair of the Health Equity Committee for Stand Up to Cancer.
Perez has served as principal investigator in the development and execution of a wide range of clinical trials exploring the use of new therapeutic agents for the treatment and prevention of breast cancer.
These clinical trials highlighted the need for basic research studies to evaluate the role of genetic markers in the development and aggressiveness of breast cancer.
[6] While she was working at the Mayo Clinic, Perez was essential to the N9831 trial, which demonstrated the impact of adding trastuzumab (Herceptin®) to improve disease-free and overall survival for patients with early-stage HER-2 positive breast cancer.